Clinical trial • Phase I • Immunology
IMP761 for Autoimmune disease
Phase I trial of IMP761 for Autoimmune disease. 79 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Autoimmune disease
- Trial Stage
- Phase I
- Drug Modality
- Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 27-05-2024
- First CTIS Authorization Date
- 16-07-2024
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 79
Recruitment
- Planned Sample Size
- 79
- Recruitment Window Months
- 25
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 79
Netherlands
- Earliest CTIS Part Ii Submission Date
- 02-07-2024
- Latest Decision Or Authorization Date
- 29-01-2026
- Processing Time Days
- 576
- Number Of Sites
- 1
- Number Of Participants
- 79
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Immunology
- Principal Investigator Name
- M. Moerland
- Principal Investigator Email
- clintrials@chdr.nl
- Contact Person Name
- M. Moerland
- Contact Person Email
- clintrials@chdr.nl
- Number Of Participants
- 79
Sponsor
Primary sponsor
- Full Name
- Immutep
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- IMP761
- Modality
- Monoclonal antibody
- First In Human
- Yes
Related trials
Other published trials that may interest you.
- BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)
- Belimumab for Systemic lupus erythematosus
- INEBILIZUMAB for Myasthenia gravis
- PREDNISONE for Granulomatosis with polyangiitis (Wegener's) | Microscopic polyangiitis | ANCA-associated vasculitis
- BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED for Allergic rhinitis due to birch pollen | Allergic rhinoconjunctivitis